Plasma Fractionation Global Market Report 2024

Plasma fractionation is the process of integrating manufacturing procedures to sequentially isolate crude fractions, which are then further refined into specific medicinal products.

The primary products in the plasma fractionation market include immunoglobulins, coagulation factors, albumin, and protease inhibitors. Immunoglobulins find application in treating a wide range of disorders, encompassing primary and secondary immune deficiencies, autoimmune diseases, and inflammatory conditions. Immunoglobulins (Ig) and antibodies, glycoproteins produced by plasma cells, play a crucial role in the immune system's recognition and neutralization of foreign objects such as pathogenic bacteria and viruses. These products have various applications in immunology, hematology, neurology, critical care, hemato-oncology, and rheumatology, with end users spanning hospitals and clinics, clinical research laboratories, and academic institutes.

The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry. This plasma fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasma fractionation market size has grown strongly in recent years. It will grow from $28.95 billion in 2023 to $31.78 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of hemophilia and immunodeficiency disorders, a rising aging population, a growing demand for immunoglobulins, the expansion of plasma collection centers, and an increase in the number of surgical procedures.

The plasma fractionation market size is expected to see rapid growth in the next few years. It will grow to $46.72 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be attributed to several factors, including the rise in global healthcare expenditure, the increasing applications of plasma-derived medicinal products, a growing investment in research and development, the demand for plasma in the treatment of neurological disorders, and the expansion of plasma fractionation facilities. Key trends expected during this period include the development of new fractionation technologies, a shift towards albumin and immunoglobulin therapies, a rising demand for specialty plasma products, a focus on pathogen inactivation technologies, and strategic collaborations and partnerships in the plasma industry.

The anticipated increase in the number of chronic diseases is set to drive the growth of the plasma fractionation market. Chronic diseases, lasting one year or more and requiring ongoing medical attention, include conditions like heart disease, cancer, and diabetes. The treatment of chronic disease patients through plasma products not only reduces morbidity but also enhances the quality of life and proves to be cost-effective. A report by the National Library of Medicine projects a 99.5% rise in individuals aged 50 years and older with one or more chronic illnesses by 2050, reaching 142.66 million, up from 71.522 million in 2020 in the United States. The surge in chronic disease cases across all age groups is expected to fuel the growth of the plasma fractionation market.

The increasing prevalence of hemophilia is poised to be a significant driver for the plasma fractionation market. Hemophilia, a rare genetic disorder affecting blood clotting, leads to prolonged bleeding episodes. Plasma fractionation is vital for producing clotting factors administered to individuals with hemophilia to facilitate blood coagulation. According to the World Federation of Hemophilia, approximately 20,000 people with hemophilia are born globally each year, with 7,000 having severe cases. In the current global male population of 3.9 billion, there are an estimated 818,928 hemophilia patients. Thus, the growing prevalence of hemophilia is expected to propel the plasma fractionation market.

A key trend gaining traction in the plasma fractionation market is technological advancements. Major companies in the market are introducing innovative technologies, such as HYCON, featuring self-cleaning and fully automatic separators, to maintain their market position. In June 2021, the Germany-based company GAE launched HYCON, a fully automatic separator facilitating one-touch production for the separation of blood plasma and plasma proteins in clean room applications. The self-cleaning and fully automatic separator contribute to improved hygienic conditions, prevention of cross-contamination, and enhanced batch safety.

Strategic investments in expanding manufacturing capabilities for plasma-derived therapies (PDTs) are a focus for major players in the industry. This involves allocating resources to develop and enhance facilities and processes for the production of specialized therapies derived from blood plasma. In April 2023, Takeda Pharmaceutical, a Japan-based biopharmaceutical company, invested ¥100 billion (approximately $755.8 million) to construct a state-of-the-art plasma-derived therapy manufacturing facility in Osaka. With a commitment to environmental sustainability, Takeda aims to achieve net-zero greenhouse gas emissions in its operations by 2035.

In April 2022, Grifols S. A., a Spain-based pharmaceutical and chemical product manufacturing company, completed the acquisition of Biotest AG for $317.03 million (EUR 318 million). Through this strategic move, Grifols aims to enhance the availability of plasma medicines, expand its product line, and strengthen its position as the largest private European network of plasma facilities with 87 locations. The acquisition is expected to drive revenue growth, profitability expansion, and accelerate the advancement of research and development projects.

Major companies operating in the in the plasma fractionation market report are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, ProMetic Life Sciences Inc., Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Shire PLC, Takeda Pharmaceutical Company, Terumo BCT, Bioverativ Inc., China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Grifols International S. A., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

North America was the largest region in the plasma fractionation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the plasma fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The plasma fractionation market includes revenues earned by entities by combining manufacturing steps to isolate, in a sequential and integrated manner. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.